Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor-specific mutant peptide-MHC complex (neoantigen-MHC complex)
- Target
- neoantigen-MHC complex
- Molecular classification
- MHC Class I complex, MHC Class II complex, Peptide-MHC complex, Cell Surface Receptor Complex
01
Overview
A tumor-specific mutant peptide-MHC complex is a molecular structure formed when a major histocompatibility complex (MHC) molecule presents a peptide derived from a tumor-specific mutation (neoantigen) on the surface of a cell. These complexes are central to immune recognition of cancer cells, as they allow T cells to distinguish and target malignant cells based on their unique, mutation-derived peptides. They are key targets for personalized cancer immunotherapies, including neoantigen vaccines and adoptive T cell therapies.
- Other names
- Neoantigen-MHC complexTumor-specific antigen-MHC complexMutant peptide-MHC complexpMHC complex (tumor-specific)Tumor-associated neoantigen presented by MHC
02
Mechanism of action
TCR binding and T cell activation; Targeted immune cell recruitment and tumor cell lysis
03
Biological functions
Antigen presentationT cell activationImmune surveillanceTumor cell recognitionAdaptive immunity
04
Disease associations
CancerImmune evasion
05
Safety considerations
Off-target toxicity (cross-reactivity with self-antigens)Cytokine release syndrome (CRS)Immune-related adverse events (irAEs)Tumor lysis syndromeDevelopment of resistance
06
Interacting drugs
Neoantigen-based vaccines
3 more in the full profile.
07
Biomarkers
Neoantigen sequenceMHC haplotype (HLA type)TCR repertoirePD-L1 expression (related, but not directly on pMHC)Tumor Mutational Burden (TMB)
Beyond the preview
Go deeper on Tumor-specific mutant peptide-MHC complex (neoantigen-MHC complex).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tumor-specific mutant peptide-MHC complex (neoantigen-MHC complex).